Jefferies Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Jefferies Group’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.47M	Buy	21,049 +11,233	+114%	+$831K	0.01%	698
2022 Q2	$659K	Sell	9,816 -65,530	-87%	-$4.17M	0.01%	913
2022 Q1	$6.19M	Buy	75,346 +27,965	+59%	+$2.86M	0.04%	361
2021 Q4	$6.95M	Buy	+47,381	New	+$7.36M	0.04%	368
2021 Q3	–	Sell	-2,854	Closed	-$459K	–	2094
2021 Q2	$461K	Sell	2,854 -7,279	-72%	-$1.17M	﹤0.01%	1188
2021 Q1	$1.74M	Sell	10,133 -87,447	-90%	-$17.3M	0.02%	728
2020 Q4	$21.4M	Buy	97,580 +13,725	+16%	+$2.97M	0.17%	98
2020 Q3	$13.9M	Sell	83,855 -3,058	-4%	-$418K	0.15%	92
2020 Q2	$9.92K	Sell	86,913 -640	-0.7%	-$62.1K	0.12%	138
2020 Q1	$6.73M	Buy	87,553 +22,932	+35%	+$2.06M	0.07%	230
2019 Q4	$8.33M	Sell	64,621 -4,772	-7%	-$460K	0.06%	292
2019 Q3	$5.41M	Buy	69,393 +69,193	+34,597%	+$6.49M	0.04%	483
2019 Q2	$21K	Buy	+200	New	+$15.6K	﹤0.01%	2424
2018 Q4	–	Sell	-1,800	Closed	-$85K	–	2685
2018 Q3	$85K	Buy	+1,800	New	+$100K	﹤0.01%	2239

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jefferies Group's MRTX Position: Q3 2022 in Review

Jefferies Group increased its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 114% in Q3 2022, buying an estimated $831K and bringing the position to 21,049 shares worth $1.47M. The position accounts for 0.01% of the portfolio, ranked #698.

Jefferies Group first reported a position in MRTX in Q3 2018 and has held it in 14 quarters since. The position peaked at $21.4M in Q4 2020. 243 funds tracked by Wall St. Rank hold MRTX as of Q3 2022.

Jefferies Group held 21,049 shares of Mirati Therapeutics, Inc. Common Stock worth $1.47M as of Q3 2022.
Jefferies Group bought 11,233 Mirati Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $831K.
Mirati Therapeutics, Inc. Common Stock made up 0.01% of Jefferies Group's portfolio in Q3 2022, its #698 holding.
Jefferies Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2018 and has held it in 14 quarters since.
Jefferies Group's Mirati Therapeutics, Inc. Common Stock position peaked at $21.4M in Q4 2020.
243 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.